Pages that link to "Q33752366"
Jump to navigation
Jump to search
The following pages link to Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule (Q33752366):
Displaying 19 items.
- Monoclonal antibodies against peptidorhamnomannans of Scedosporium apiospermum enhance the pathogenicity of the fungus (Q27306696) (← links)
- Opsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans (Q33559279) (← links)
- Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies. (Q33693515) (← links)
- Bivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule (Q33752377) (← links)
- Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations (Q33975989) (← links)
- Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice (Q34001701) (← links)
- Antibody interactions with the capsule of Cryptococcus neoformans (Q34004832) (← links)
- Capsular reactions of Cryptococcus neoformans with polyspecific and oligospecific polyclonal anticapsular antibodies (Q34006122) (← links)
- Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity (Q34123230) (← links)
- Of mice and men, revisited: new insights into an ancient molecule from studies of complement activation by Cryptococcus neoformans (Q34680995) (← links)
- Contribution of epitope specificity to the binding of monoclonal antibodies to the capsule of Cryptococcus neoformans and the soluble form of its major polysaccharide, glucuronoxylomannan (Q34779166) (← links)
- Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection. (Q35689463) (← links)
- Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans (Q35923662) (← links)
- Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans (Q37161587) (← links)
- The capsule of the fungal pathogen Cryptococcus neoformans (Q37337879) (← links)
- An opsonizing monoclonal antibody that recognizes a noncapsular epitope expressed on Cryptococcus neoformans. (Q39512151) (← links)
- Specific antibody can prevent fungal biofilm formation and this effect correlates with protective efficacy (Q43013288) (← links)
- Complement activation by pathogenic fungi (Q77164019) (← links)
- New insights on the pathogenesis of invasive Cryptococcus neoformans infection (Q81593297) (← links)